Key result
Traditional and novel pharmacotherapies are reviewed for the symptom relief and long-term management of refractory angina, alongside current European and US cardiovascular society recommendations.
Why the study?
What are the pharmacological approaches for symptom relief and long-term management in patients with refractory angina?
What are the pharmacological approaches for symptom relief and long-term management in patients with refractory angina?
This review provides a comprehensive overview of current and novel pharmacological strategies and guideline recommendations for managing refractory angina in patients who are suboptimal candidates for revascularization.
Rising refractory angina incidence highlights unmet needs; leaves open targeted therapy development in this population.
Refractory angina refers to a group of patients with stable coronary atherosclerotic disease and angina symptoms, unresponsive to traditional medical management, while considered to be suboptimal candidates for revascularization procedures. Up to 15% of angina patients are considered to have refractory angina and, taking into account the aging population and the improvements in the treatment of stable coronary artery disease, the incidence of this entity is expected to increase. This review describes traditional and novel pharmacotherapies for symptoms relief and for long-term management of refractory angina. Mechanisms of action and relevant clinical trials are discussed and current recommendations from major European and US cardiovascular societies are reported.
No takes yet. Share an insight, caveat, or question.
Giannopoulos et al. (2016) conducted a review in Refractory angina. Pharmacotherapies was evaluated. Traditional and novel pharmacotherapies are reviewed for the symptom relief and long-term management of refractory angina, alongside current European and US cardiovascular society recommendations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: